Selected article for: "acute respiratory syndrome and little sars cov"
Author: Li, Tingting; Zhang, Tianying; Gu, Ying; Li, Shaowei; Xia, Ningshao
Title: Current Progress and Challenges in the Design and Development of a Successful COVID-19 Vaccine
  • Cord-id: 7gmaw1d9
  • Document date: 2021_1_26
    • ID: 7gmaw1d9
    Snippet: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still a worldwide concern, with little to no sign of a decreasing trend. There is a general consensus that normal life will be hampered until a safe and effective vaccine strategy is available and globally administered. Numerous countries have accelerated the clinical trials process for the development of a successful COVID-19 treatment, with over 200 candidates presently
    Document: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still a worldwide concern, with little to no sign of a decreasing trend. There is a general consensus that normal life will be hampered until a safe and effective vaccine strategy is available and globally administered. Numerous countries have accelerated the clinical trials process for the development of a successful COVID-19 treatment, with over 200 candidates presently available for testing against SARS-CoV-2. Here, we provide an overview of the COVID-19 vaccine candidates currently in development, discuss the scientific and practical challenges associated with COVID-19 vaccine design, and share the potential strategies that could be exploited for vaccine design success.

    Search related documents:
    Co phrase search for related documents
    • adaptive immunity and address need vaccine: 1
    • adaptive immunity and ade antibody dependent enhancement: 1
    • adaptive immunity and administration route: 1, 2
    • adaptive immunity and long short: 1, 2
    • adaptive immunity and long short term: 1
    • additional dose and long short: 1
    • additional dose and long short term: 1
    • address need and adequate assessment: 1
    • address need and administration route: 1, 2
    • address need and long short: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • address need and long short term: 1, 2, 3, 4, 5, 6, 7
    • address need and low dose medium: 1
    • ade antibody dependent enhancement and administration route: 1, 2
    • adequate assessment and long short: 1
    • adequate assessment and long short term: 1
    • administration route and long short: 1